Getting tirzepatide, and what it costs

The cheapest published price, and the catch in it

The cheapest published price for a month of tirzepatide is Lilly’s own, and what it buys changes as the dose does. The starting dose is the advertised number. The doses people settle on are higher, and they carry a refill clock: buy the next one late and the same box costs several hundred dollars more.

There is a second thing in the federal data worth knowing before paying anyone else less. The CMS acquisition file records what pharmacies report paying to buy the same Zepbound KwikPen, and at the maintenance doses that figure sits above Lilly’s own direct price. Both numbers are published, both carry their own dates, and what sits between them is not something anyone publishes.

The two figures are on the cost pages with their working shown, because a monthly figure built from a per-milliliter federal number is arithmetic and should look like it.

The whole ladder

Lilly prices Zepbound dose by dose, and the price stops climbing partway up. The condition on the flat part is a refill clock.

Read from Lilly’s own terms on 2026-08-12. The exclusions, the caps and the insured lane are on the Zepbound cost page.

What a pharmacy pays for the same box

That is what pharmacies report paying to buy it. Nobody is charged it and it is not an offer. Put beside Lilly’s own maintenance price it sits higher, which is worth knowing before paying a third party less than the manufacturer charges. What settles in the gap is not published by anyone.

The Mounjaro gap

Lilly’s Mounjaro page says the drug is available through LillyDirect for self-pay and stops there. No price, no dose table, no month definition. We are not going to fill that gap with a number from a pharmacy or a discount site, because it would move next week and it would not be Lilly’s.

The insured route for Mounjaro is on its own cost page, with the card’s caps and the exclusion quoted.

NICE publishes a different price ladder and NHS England applies a staged access pathway. Those country-specific facts are kept in the UK Mounjaro record, not blended into this United States page.

Every route, for this drug

The same seven routes as the rest of the section, read against a drug with two approved brands and one published cash ladder.

1. A prescription from a clinician you see

   Open

   The ordinary route. A doctor, nurse practitioner or physician assistant assesses you and writes a prescription, and a pharmacy fills it.

   Prescription

   Yes, and it is not optional. Federal law makes every drug on this site prescription-only, which means it cannot lawfully be sold to you without one.

   What is published about cost

   Whatever your plan charges, plus the manufacturer’s savings card if your plan covers the drug. The cards take most people to about $25 a month.

   Who it does not work for

   Nobody, in principle. In practice the delay is getting an appointment, and plans differ wildly on whether they cover a GLP-1 for weight at all.

2. A prescription from a telehealth service

   Conditions apply

   You fill in a questionnaire or take a video call, a clinician the service works with writes the prescription, and a pharmacy ships it.

   Prescription

   Yes. The law does not treat a telehealth prescription differently. What changes is who you are talking to and what they are selling.

   What is published about cost

   Set by the service, and it usually bundles the visit, the drug and the follow-up into one monthly fee. Those fees are not published in one place and they move.

   Who it does not work for

   Anyone the service decides not to take. Some will not work with insurance at all, so the fee is on top of whatever else you pay.

   In FDA’s letters

   This is where FDA’s letters land hardest. The largest single group in the published research is telehealth companies, and the two things FDA describes most are claims the advertising could not support and drugs sold without approval.

3. Buying direct from the manufacturer

   Conditions apply

   Eli Lilly and Novo Nordisk both sell some of their own products for cash, through their own pharmacies, at prices they publish.

   Prescription

   Yes. Buying direct changes who ships the box, not whether a prescription is needed.

   What is published about cost

   Published, dose by dose, on the manufacturer’s own site. It is the only cash lane on this page where the price is written down and dated.

   Who it does not work for

   Not everything is in it. Lilly publishes a full cash ladder for Zepbound and none at all for Mounjaro, and Novo Nordisk prices its starting strengths well below the ones people settle on.

   In FDA’s letters

   Both manufacturers have received FDA warning letters about how they advertised these drugs. We include those letters under the same rules used for every other company.

4. Your own insurance

   Conditions apply

   A commercial plan covers the drug, you pay a copay, and a manufacturer savings card usually covers most of what is left.

   Prescription

   Yes, and the plan often wants more: a prior authorization, a documented reason, sometimes a weight or a diagnosis.

   What is published about cost

   About $25 a month on every card here, while the card lasts. Each card caps what it will pay in a month and in a year, and the caps differ by product.

   Who it does not work for

   Every one of these cards excludes anyone on Medicare, Medicaid, TRICARE or VA coverage. The exclusions are quoted word for word on each product’s cost page, because that is where a reader loses money.

5. Medicare’s GLP-1 Bridge

   Conditions apply

   A federal program that puts some GLP-1 drugs at a fixed monthly price for people with Medicare drug coverage. It runs on a stated end date.

   Prescription

   Yes, plus a prior authorization, and your prescriber has to certify a diet and exercise program as well.

   What is published about cost

   $50 a month. None of it counts toward the Part D out-of-pocket limit, and there is no low-income subsidy on it.

   Who it does not work for

   It covers three named products and no others. It also rules out anyone whose reason for taking a GLP-1 is type 2 diabetes, which puts Ozempic and Mounjaro outside it entirely.

6. A compounded copy from a pharmacy

   Basis ended

   A pharmacy mixes its own version rather than dispensing an approved product. Nobody checks it for safety, strength or quality first.

   Prescription

   Yes. A compounded drug is still a prescription drug, and under section 503A it needs a prescription with your name on it.

   What is published about cost

   Whatever the seller charges. There is no published price for a compounded preparation because there is no product to publish one for.

   Who it does not work for

   The legal basis for large-scale compounding of these two drugs was the shortage listing, and both shortages ended. The windows closed in March and May 2025.

   In FDA’s letters

   Compounding pharmacies appear in the published research in their own right. FDA inspected the places that mixed the drug, and several of those letters describe what it found there.

7. A site selling it as a research chemical

   No lawful route

   A website sells a vial of powder labeled for laboratory use, usually with a line saying it is not for human consumption.

   Prescription

   Nobody asks you for one, and that is the tell. A seller who does not need a prescription is not selling you a medicine, whatever the vial says.

   What is published about cost

   Cheap, and the price is the product. Nothing about what is in the vial is established by anyone: not the strength, not the purity, not that it is the drug on the label.

   Who it does not work for

   There is no lawful route here to a person. These are unapproved drugs, and selling one to a consumer in the United States is what most of FDA’s letters to these sites are about.

   In FDA’s letters

   A large block of the published research is exactly this: sites offering unapproved drugs to United States consumers over the internet. Several letters name a web address rather than a company.

Where the compounded route stands

The legal basis for large-scale compounding of these two drugs was the shortage listing, and both shortages ended. The windows closed in March and May 2025.

Tirzepatide is not on FDA’s shortage list, checked 14 August 2026.

Status comes from FDA’s drug shortage database on the date shown. The list changes daily. openFDA, read 2026-08-14.

The declaratory orders, the litigation and both deadlines are in the compounded tirzepatide record.

What FDA’s letters show for tirzepatide

FDA has published 109 warning letters that mention tirzepatide somewhere in the text, read on 12 August 2026. 106 of them were issued in the last 24 months and are named on this site.

Tirzepatide is named across a large share of the published warning-letter record, and the letters are not mostly about the manufacturer. They are about telehealth services, compounding pharmacies and websites.

Lilly itself has received letters about how Zepbound and Mounjaro were advertised. Those sit in the same record.

All 106 of them are listed with FDA’s own wording, both dates and the close-out column at the enforcement record.

Questions people actually ask

The pages behind this one